Galectin Therapeutics Inc. (GALT)
Oxford Ledge is still expanding full research coverage of GALT. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A biopharmaceutical company developing galectin-3 inhibitors derived from plant-based carbohydrates to treat liver fibrosis and cancer.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-23
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-03-31
- 10-K Annual financial report with audited statements 2026-03-31
Source: SEC EDGAR.
Annual results
5 years of annual figures for GALT, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$30.8M | -$0.48 |
| 2024 | — | -$47.0M | -$0.76 |
| 2023 | — | -$41.1M | -$0.74 |
| 2022 | — | -$38.8M | -$0.65 |
| 2021 | — | -$30.5M | -$0.52 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for GALT. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GALT in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.